secwatch.observer — SEC 8-K summary
======================================

Issuer:     Foghorn Therapeutics Inc. (FHTX)
CIK:        0001822462
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001628280-25-001226
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders
--------------------------------------------------------------------------------

- Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.
- Phase 1 trial of oral SMARCA2 inhibitor FHD-909 for SMARCA4-mutated cancers advancing; NSCLC primary target.
- Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors to be presented at AACR April 2025.
- Selective ARID1B degradation achieved; program update expected in 2025. ARID1B implicated in up to 5% of solid tumors.
- Selective CBP and EP300 degrader programs advancing with preclinical data showing anti-tumor activity and tolerability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/0001628280-25-001226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822462/000162828025001226/fhtx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-001226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer